Compare Atlassian Corporation PLC (TEAM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs BIO-TECHNE Corp — how do they compare? Atlassian Corporation PLC trades at $178.15 (market cap $44.66B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Atlassian Corporation PLC is far larger — about 3.9× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| TEAM | TECH | |
|---|---|---|
Market Cap | $44.66B | $11.34B |
Sector | Technology | Health |
52-Week High | $194.68 | $72.48 |
52-Week Low | $57.15 | $43.31 |
Enterprise Value | $44.65B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $176.42, down 6.94% on the day, despite strong recent performance with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with support at $173 and resistance at $182. Revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable with a -0.82% net income margin. Analyst consensus is strongly bullish with 30 buy ratings and a $179.81 price target, while recent news highlights AI integration driving cloud growth.
TEAM presents a growth-oriented investment with significant upside potential from AI adoption and market expansion, but carries risks from persistent losses, premium valuation (P/S 6.98), and insider selling. The path to profitability remains key, with projected net losses narrowing to -$54M in 2026. Investors should weigh strong analyst support against high execution demands in a competitive SaaS landscape.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
